10-Q: Skinvisible Inc. Reports Third Quarter 2024 Results Amidst Going Concern Uncertainty

Skinvisible Inc. reports a net loss of $880,425 for the nine months ended September 30, 2024, while facing substantial doubt about its ability to continue as a going concern.

Summary

• Skinvisible Inc. reported a net loss of $286,604 for the three months ended September 30, 2024, and a net loss of $880,425 for the nine months ended September 30, 2024.
• The company's revenue remained consistent at $5,000 for the three-month period and $15,000 for the nine-month period, compared to the same periods in 2023.
• Operating expenses increased to $129,969 for the three months and $405,846 for the nine months ended September 30, 2024.
• The company's total assets were $148,643, with total current liabilities of $4,643,708 as of September 30, 2024.
• Skinvisible has a working capital deficit of $4,616,304 as of September 30, 2024.
• The company's financial statements have been prepared on a going concern basis, but there is substantial doubt about its ability to continue operations due to cumulative net losses of $40,260,913 since inception and the need for additional capital.
• The company is seeking additional funding through licensing and potential debt and equity financing.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a significant net loss, a large working capital deficit, and a going concern warning. While there are some positive developments in clinical trials, the overall sentiment is negative due to the company's financial instability and operational challenges.

Positives

• The net loss for the nine months ended September 30, 2024, decreased to $880,425 from $2,078,649 in the same period of 2023.
• The company is actively pursuing strategic partnerships to monetize its patent applications for transdermal delivery of obesity and glucose-controlling agents.
• Quoin Pharmaceuticals, a licensee of Skinvisible, has made progress in clinical trials for its product QRX003, which utilizes Skinvisible's Invisicare technology, including FDA clearance to recruit teen subjects.

Negatives

• The company's revenue has remained stagnant at $5,000 for the three months and $15,000 for the nine months ended September 30, 2024.
• Skinvisible has incurred cumulative net losses of $40,260,913 since its inception.
• The company has a significant working capital deficit of $4,616,304 as of September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed ineffective due to material weaknesses in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain due to its history of losses and need for additional capital.
• There is a risk that the company may not be able to secure additional financing through licensing, debt, or equity arrangements.
• The company's disclosure controls and procedures are not effective due to material weaknesses in internal control over financial reporting.
• The company faces risks related to its operations, business plan, and strategy, as well as changes in economic conditions and competition.
• There are risks associated with protecting intellectual property rights and potential claims of infringement.

Future Outlook

The company plans to generate more revenues from its licenses with Quoin and Ovation, and to enter into commercial arrangements with pharma and biotech companies to exploit its patent applications. They also plan to seek additional financing in a private equity offering to secure funding for operations.

Management Comments

• Management believes that the opportunity to license their products continues to be a viable model.
• Management plans to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding.
• Management believes that the protocol amendments in Quoin's clinical trials could ultimately result in the generation of a highly compelling data set, which could support regulatory filings and approval for QRX003.

Industry Context

The company operates in the pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas, targeting an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market. The company's business model of out-licensing its patented products aligns with the trend of pharmaceutical companies seeking external R&D for new products.

Comparison to Industry Standards

• It is difficult to compare Skinvisible directly to industry standards due to its unique business model of licensing its patented technology rather than manufacturing and selling products directly.
• Many pharmaceutical and biotech companies with similar R&D focus often have significantly higher revenues and lower losses, but these companies also have higher operating costs associated with manufacturing and sales.
• Companies like Quoin Pharmaceuticals, which are licensing Skinvisible's technology, are more comparable in terms of R&D focus, but their financial performance is not directly comparable as they are at different stages of development and have different revenue models.
• The company's reliance on licensing revenue makes it vulnerable to the success of its licensees, and its financial performance is heavily dependent on the progress of clinical trials and regulatory approvals of its licensed products.

Related Party Transactions

• During the nine months ended September 30, 2024 and 2023, the Company was advanced $5,614 and $2,000 and repaid $1,800 and $0 to related parties.
• As of September 30, 2024 and December 31, 2023, the Company had amounts due from related parties of $9,364 and $6,000, respectively.
• On January 31, 2023, the Company renegotiated accrued salaries, vacation, and outstanding convertible notes for its two officers, converting them to promissory notes convertible into common stock with a warrant feature.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company fails to secure additional funding.
• Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to seek additional financing through a private equity offering.
• The company intends to continue pursuing licensing agreements for its patented products.
• The company will continue to monitor the progress of clinical trials for its licensed products.
• The company plans to implement changes to remediate material weaknesses in internal control over financial reporting during the fiscal year ending December 31, 2025.

Key Dates

Keywords

Invisicare, licensing, transdermal delivery, pharmaceutical, dermatology, obesity, glucose control, clinical trials, patents, financial results, going concern